Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 32, Issue 25, Pages 2699-+Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2013.50.0892
Keywords
-
Categories
Funding
- Walter Reed National Military Medical Center
- Armed Forces Medical Surveillance Agency
Ask authors/readers for more resources
Purpose Patients with immunoglobulin light chain amyloidosis (AL amyloidosis) generally present with advanced organ dysfunction and have a high risk of early death. We sought to characterize monoclonal immunoglobulin (M-Ig) light chains before clinical presentation of AL amyloidosis. Patients and Methods We obtained prediagnostic sera from 20 cases with AL amyloidosis and 20 healthy controls matched for age, sex, race, and age of serum sample from the Department of Defense Serum Repository. Serum protein electrophoresis with immunofixation and serum free light chain (FLC) analysis were performed on all samples. Results An M-Ig was detected in 100% of cases and 0% of controls (P < .001). The M-Ig was present in 100%, 80%, and 42% of cases at less than 4 years, 4 to 11 years, and more than 11 years before diagnosis, respectively. The median FLC differential (FLC-diff) was higher in cases compared with controls at all time periods, less than 4 years (174.8 v 0.3 mg/ L; P < .001), 4 to 11 years (65.1 v 2.2 mg/ L; P < .001), and more than 11 years (4.5 v 0.4 mg/ L; P = .03) before diagnosis. The FLC-diff was greater than 23 mg/ L in 85% of cases and 0% of controls (P < .001). The FLC-diff level increased more than 10% per year in 84% of cases compared with 16% of controls (P < .001). Conclusion Increase of FLCs, including within the accepted normal range, precedes the development of AL amyloidosis for many years. (C) 2014 by American Society of Clinical Oncology
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available